Mazdutide

Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor agonist studied for chronic weight management and metabolic improvement, with clinical data showing meaningful weight loss but investigational status in most markets.

Profile · 01

Overview

Mazdutide is a long-acting dual agonist at GLP-1 and glucagon receptors. The source positions it as a metabolic peptide that combines appetite suppression and glycemic support with increased energy-expenditure signaling, distinguishing it from single-pathway GLP-1 agonists.

Unlike many entries in this library, mazdutide has human Phase 2 and Phase 3 data behind it. The source notes that it had received initial approval in China in 2025, while remaining investigational in most other countries. This page summarizes the conservative once-weekly titration path from that source.

At a Glance

Goal
Support chronic weight management and metabolic improvement through dual GLP-1 and glucagon receptor activation
Categories
Weight ManagementMetabolic HealthGLP-1 AgonistGlucagon Agonist
Synergistic
Protein intake · Electrolytes · Resistance training · Sleep hygiene
Profile · 02

Protocol

Standard weekly titration approach mirroring clinical-trial patterns with a four-week run-in period.

Reconstitute
Add 3.0 mL bacteriostatic water to a 5 mg vial for about 1.67 mg/mL concentration
Typical weekly range
2.5-5 mg once weekly; advanced protocols in the source discuss 7.5-10 mg
Start
2.5 mg weekly for Weeks 1-4
Target
5 mg weekly by Weeks 5-8 and beyond
Frequency
Once weekly (subcutaneous)
Cycle Length
8-12 weeks minimum; source also cites longer clinical use up to 48 weeks
Timing
Use the same day each week and rotate injection sites
Route
Subcutaneous
Cycle
8-48 weeks depending on goals and tolerability

Inject once weekly subcutaneously and titrate slowly to improve tolerability. The source presents 2.5 mg for four weeks before moving to 5 mg as the standard pathway. It also discusses higher experimental dosing, but GI side effects rise with dose and those higher ranges deserve extra caution.

Dose progression

Weeks 1-4
2.5 mg · 150 units (1.50 mL)
Weeks 5-8+
5.0 mg · 300 units (3.00 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How Mazdutide works.

Mazdutide activates GLP-1 receptors for appetite suppression, slowed gastric emptying, and glycemic support while also activating glucagon receptors to increase energy expenditure and fat oxidation. That dual mechanism is the central reason it is discussed as distinct from single-pathway incretin agents.

The source cites Phase 2 and Phase 3 human data showing clinically meaningful weight reduction and glycemic improvement. This makes mazdutide one of the more evidence-backed metabolic entries in the library, though long-term safety and jurisdiction-specific approval status still matter.

Science · 02

Effects

Observations from clinical or preclinical literature.

Clinical studies report meaningful body-weight reduction over 24-48 weeks
Human data also suggest improvements in HbA1c and broader metabolic markers
Once-weekly dosing can improve adherence compared with daily regimens
GI side effects such as nausea, vomiting, diarrhea, or constipation are the most common tolerability limit
Injection-site irritation may occur
Slower titration generally improves adherence and comfort
Science · 03

Caution

Not recommended during pregnancy or breastfeeding because safety data is insufficient
Avoid in personal or family history of medullary thyroid carcinoma or MEN2 in line with GLP-1 class precautions
Use caution with pancreatitis history or severe gastrointestinal disease
Use caution with concurrent insulin or sulfonylureas because glucose-lowering interactions may matter

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Protein intake
Critical for preserving lean mass during weight loss.
Electrolytes
Helpful when nausea or reduced intake causes depletion.
Vitamin D
Supports overall metabolic health and is often low in obesity.
B-complex vitamins
Support energy metabolism during caloric restriction.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Use resistance training and adequate protein intake to defend lean mass during weight loss
Stay hydrated and monitor electrolytes, especially early in titration when GI effects are more likely
Maintain a nutrient-dense eating pattern rather than relying on appetite suppression alone
Prioritize sleep and recovery because fatigue and under-recovery can worsen tolerability
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body weight and waist circumference - weekly trend tracking is more useful than daily fluctuations
  2. Appetite and satiety - helps gauge response to dual agonist signaling
  3. GI tolerance - note nausea, bowel changes, and hydration status
  4. Fasting glucose - useful especially in insulin-resistant or diabetic contexts
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

HbA1c
Primary glycemic-control marker for longer protocols.
Fasting glucose and insulin
Useful for metabolic-response tracking.
Lipid panel
Tracks cardiovascular-metabolic changes over time.
CMP (Comprehensive Metabolic Panel)
Assesses liver and kidney function during the protocol.
Lipase and amylase
Reasonable to monitor when pancreatitis risk is a concern.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 5 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry fully
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites across the abdomen, front or outer thighs, and upper arms
If a selected dilution creates a large volume, split the dose into separate injections as needed

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile syringe for each injection and dispose of it safely
GI side effects are dose-dependent, so slower titration is usually the most practical way to improve adherence
The source standard dilution creates large injection volumes; many researchers will prefer a more concentrated setup or split injections
Mazdutide remains investigational in most countries despite the source noting initial China approval in 2025
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. EClinicalMedicine / PubMed
    Phase 1b mazdutide trial in adults with overweight or obesity.
    https://pubmed.ncbi.nlm.nih.gov/36247927/
  2. Nature Communications
    Phase 2 randomized controlled trial of mazdutide in overweight or obese adults.
    https://www.nature.com/articles/s41467-023-44067-4
  3. New England Journal of Medicine / PubMed
    Phase 3 once-weekly mazdutide trial results in obesity or overweight.
    https://pubmed.ncbi.nlm.nih.gov/40421736/
  4. Diabetes Care / PubMed
    Phase 2 mazdutide study in type 2 diabetes.
    https://pubmed.ncbi.nlm.nih.gov/37482087/
  5. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
On this page